NDRA
ENDRA Life Sciences Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 31 ENDRA Life Sciences reported Q4 and full-year 2025 financial results…
- R Apr 21 ENDRA Life Sciences (NDRA) received a delisting notice from Nasdaq d…
- R May 28 ENDRA Life Sciences announced a ~$3.8 million private placement on M…
- R Oct 1 ENDRA Life Sciences filed a First Amendment to its Merger Agreement…
- R Oct 8 ASP Isotopes Inc. and its wholly owned subsidiary LHE LNG Holdings L…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 2 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$1.140 → −$0.840 over 90 days. 1 up, 0 down in 30 days.
- TrendDOWNTREND
12% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $79.5K |
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $39.1K |
| UBS Group AG | TRIM | $362.00 |
| MORGAN STANLEY | TRIM | $16.5K |
| UBS Group AG | DOUBLED | $707.00 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | TRIM | $86.00 |
| UBS Group AG | NEAR_EXIT | $54.00 |
| BANK OF AMERICA CORP /DE/ | ADD | $45.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jun 2026Price is below the lowest target. Median implies +424%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 1, 2026 | Ascendiant Capital MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 2, 2026 | Tokman Alexander Y Chief Executive Officer | AWARD | 26,921 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.84 | -$0.84–-$0.84 | +26.3% | $0.00 |
| Next Q | -$0.84 | -$0.84–-$0.84 | +26.3% | $0.00 |
| Current FY | -$3.54 | -$3.54–-$3.54 | +23.9% | $0.00 |
| Next FY | -$3.04 | -$3.04–-$3.04 | +24.0% | $200.0K |
Short side
FINRA· Oct 15, 2026SecBot reports
13 filings · 1 bullish · 3 bearish · 1 mixed · 8 neutral- NEUTRAL 425Oct 26, 2026
ASP Isotopes Inc. announced that its subsidiary Renergen's Virginia Gas Project has achieved stable liquid helium production, a key operational milestone. The filing is a Rule 425 communication related to the pending merger with ENDRA Life Sciences Inc., but contains no new deal terms or financial…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 3Oct 8, 2026
ASP Isotopes Inc. and its wholly-owned subsidiary LHE LNG Holdings LLC filed Form 3 initial…
This is a routine Form 3 filing with no trading signal. Monitor for stockholder approval of the underlying shares, which would trigger exercisability of a large portion of the warrants and…
- BULLISH SC 13DOct 8, 2026
ASP Isotopes Inc. and its wholly owned subsidiary LHE LNG Holdings LLC filed a Schedule 13D…
The 13D confirms ASP Isotopes' intent to consummate the merger and exercise pre-funded warrants to vote at the special meeting. The key catalyst is the shareholder vote on the merger; approval is…
- MIXED 425Oct 1, 2026
ENDRA Life Sciences filed a First Amendment to its Merger Agreement with ASP Isotopes Inc…
The removal of warrant exercise caps clears a path for the ASPI affiliate to take a controlling stake in ENDRA post-merger, which is structurally bullish for deal completion but bearish for existing…
All NDRA filing & press-release reports (13)
- 425 reportOct 26, 2026
- 3 reportOct 8, 2026
- SC 13D reportOct 8, 2026
- 425 reportOct 1, 2026
- 8-K reportOct 1, 2026
- 425 reportSep 25, 2026
- 425 reportSep 9, 2026
- 8-K reportAug 17, 2026
- 425 reportJul 17, 2026
- 8-K reportJul 9, 2026
- 8-K reportMay 28, 2026
- 8-K reportMar 31, 2026
- 8-K reportApr 21, 2026